Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04899492
Other study ID # ICO-2020-14
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date September 29, 2021
Est. completion date September 2024

Study information

Verified date February 2024
Source Institut Cancerologie de l'Ouest
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This trial offers support and assistance to patients wishing to quit smoking in order to increase the success rate of smoking cessation and all the benefits associated with it. Patients will be monitored by a tobacco specialist and will be able to benefit from one or more therapies complementary to Nicotine Replacement Therapy (NRT): Motivational Interviewing (MI), Cognitive Behavioural Therapy (CBT) or Hypnotherapy.


Description:

The study RESPIRE is aiming to identify some interventions to be proposed as part of a smoking cessation programme for smokers with cancer requiring surgical treatment and wishing to stop smoking. We aim to compare different smoking cessation methods in addition to the currently recommended treatments: Nicotine Replacement Therapy (NRT). These procedures are: Cognitive Behavioural Therapy (CBT), Motivational Interviewing (MI) or hypnotherapy in order to improve the success rate of smoking cessation in this specific population. All patients wishing to be supported to stop smoking will be randomized and will be followed by a tobacco specialist before and after surgery. They will receive NRT for 12 months. Smoking assessment, exhaled CO measurement, questionnaires will be completed regularly to assess depression, anxiety and quality of life during the 12 months. Patients randomized in group 2 will receive 1 to 3 MI. Patients randomized in group 3 will receive 1 to 3 MI and 6 CBT sessions by a psychotherapist. Patients randomized in group 4 will receive 1 to 3 MI and at least 3 sessions oh hypnotherapy.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 100
Est. completion date September 2024
Est. primary completion date September 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age = 18 years. - Smoking patient: daily tobacco consumption. - Patient with cancer requiring surgical treatment (breast cancer, digestive cancer, gynecological). - Patient wishing to quit smoking. - Fagerström > 3. - Patient has valid health insurance - Information and agreement of the patient to participate in the longitudinal cohort. - Signing of specific informed consent for patients in groups 1 to 4 before any study-related intervention. - Person able to speak, read and understand French. Exclusion Criteria: - Patient not receiving surgical treatment. - Refusal to participate in the longitudinal cohort study. - Pregnant or likely to be pregnant or nursing patient. - Persons deprived of their liberty, under a measure of safeguard of justice, under guardianship or placed under the authority of a guardian - disability to undergo the medical follow-up of the trial for geographical, social or psychological reasons.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Motivational Interviewing (MI)
1 to 3 Motivational Interviewing (MI) should be performed after randomization by a psychotherapist
Cognitive Behavioural Therapy (CBT)
6 Cognitive Behavioural Therapy (CBT) sessions should be performed after motivational interviewing up to 6 months by a psychotherapist
Hypnotherapy
About 3 Hypnotherapy sessions should be performed after motivational interviewing up to 6 months by a hypnotherapist
Drug:
Nicotine Replacement Therapy (NRT)
All patients will receive Nicotine Replacement Therapy (NRT) from randomization up to 6 months

Locations

Country Name City State
France Institut de Cancerologie de l'Ouest (ICO) Saint-Herblain

Sponsors (2)

Lead Sponsor Collaborator
Institut Cancerologie de l'Ouest National Cancer Institute, France

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Testing the feasibility of smoking cessation interventions evaluated in French cancer patients undergoing surgery Number of patients who completed all planned sessions out of the total number of patients randomised to each group 12 months
Secondary Evaluate the efficacy of the following interventions for smoking cessation in French cancer patients: MI, CBT and Hypnotherapy, combined with nicotine replacement therapy Percentage of patients with an exhaled Carbone Monoxide (CO) measurement < 10 ppm at study visits. 12 months
Secondary Evaluate the efficacy of the following interventions for smoking cessation in French cancer patients: MI, CBT and Hypnotherapy, combined with nicotine replacement therapy Percentage of patients reporting no smoking during the last 7 days before the visit. 12 months
Secondary Evaluate the efficacy of the different interventions in reducing tobacco consumption Number of cigarettes smoked per day from baseline 12 months
Secondary Evaluate the efficacy of the different interventions in terms of continued abstinence since surgery Percentage of patients reporting no smoking since surgery 12 months
Secondary Evaluate the reduction in side effects of oncological treatments after smoking cessation Report all Grade > 1 side effects of oncology treatments up to 3 months after the end of treatment or the end of the study 3 month
Secondary Estimate the decrease in surgical complications Report all surgical complications (Grade > 1 according to Clavien Dindo classification) up to 1 month after surgery 1 month
Secondary Evaluate the efficacy of interventions on patient depression and anxiety Patient Depression and anxiety will be evaluated by using the Hospital Anxiety and Depression Scale (HADS) 12 months
Secondary Evaluate the efficacy of interventions on patient quality of life Patient quality of life will be evaluated by using the Quality of Life Questionnaire (QLQ-C30) 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A